Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1600
0.00 (0.00%)
Sep 23, 2025, 10:38 AM AEST
Invex Therapeutics Revenue
In the fiscal year ending June 30, 2025, Invex Therapeutics had annual revenue of 229.08K AUD, down -81.10%. Invex Therapeutics had revenue of 229.08K in the half year ending June 30, 2025, with 1,781.59% growth.
Revenue
229.08K
Revenue Growth
-81.10%
P/S Ratio
52.49
Revenue / Employee
n/a
Employees
n/a
Market Cap
12.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 229.08K | -983.17K | -81.10% |
| Jun 30, 2024 | 1.21M | 753.17K | 164.06% |
| Jun 30, 2023 | 459.09K | 276.83K | 151.90% |
| Jun 30, 2022 | 182.25K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Telix Pharmaceuticals | 1.01B |
| Ansell | 3.06B |
| Mesoblast | 26.23M |